50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,671.82 (-0.58%)
DOW   29,391.31 (-0.67%)
QQQ   274.55 (-0.35%)
AAPL   150.74 (+0.21%)
MSFT   238.20 (+0.12%)
META   136.94 (-2.47%)
GOOGL   98.02 (-0.73%)
AMZN   114.89 (+0.98%)
TSLA   275.97 (+0.23%)
NVDA   122.90 (-1.81%)
NIO   17.63 (-0.06%)
BABA   79.22 (+0.53%)
AMD   66.66 (-1.91%)
T   15.73 (-1.75%)
MU   49.06 (-2.08%)
CGC   2.76 (-2.82%)
F   11.99 (-2.60%)
GE   64.77 (+0.34%)
DIS   98.35 (-1.16%)
AMC   7.37 (-7.76%)
PYPL   85.07 (-2.18%)
PFE   43.84 (-0.54%)
NFLX   224.57 (-0.81%)
S&P 500   3,671.82 (-0.58%)
DOW   29,391.31 (-0.67%)
QQQ   274.55 (-0.35%)
AAPL   150.74 (+0.21%)
MSFT   238.20 (+0.12%)
META   136.94 (-2.47%)
GOOGL   98.02 (-0.73%)
AMZN   114.89 (+0.98%)
TSLA   275.97 (+0.23%)
NVDA   122.90 (-1.81%)
NIO   17.63 (-0.06%)
BABA   79.22 (+0.53%)
AMD   66.66 (-1.91%)
T   15.73 (-1.75%)
MU   49.06 (-2.08%)
CGC   2.76 (-2.82%)
F   11.99 (-2.60%)
GE   64.77 (+0.34%)
DIS   98.35 (-1.16%)
AMC   7.37 (-7.76%)
PYPL   85.07 (-2.18%)
PFE   43.84 (-0.54%)
NFLX   224.57 (-0.81%)
S&P 500   3,671.82 (-0.58%)
DOW   29,391.31 (-0.67%)
QQQ   274.55 (-0.35%)
AAPL   150.74 (+0.21%)
MSFT   238.20 (+0.12%)
META   136.94 (-2.47%)
GOOGL   98.02 (-0.73%)
AMZN   114.89 (+0.98%)
TSLA   275.97 (+0.23%)
NVDA   122.90 (-1.81%)
NIO   17.63 (-0.06%)
BABA   79.22 (+0.53%)
AMD   66.66 (-1.91%)
T   15.73 (-1.75%)
MU   49.06 (-2.08%)
CGC   2.76 (-2.82%)
F   11.99 (-2.60%)
GE   64.77 (+0.34%)
DIS   98.35 (-1.16%)
AMC   7.37 (-7.76%)
PYPL   85.07 (-2.18%)
PFE   43.84 (-0.54%)
NFLX   224.57 (-0.81%)
S&P 500   3,671.82 (-0.58%)
DOW   29,391.31 (-0.67%)
QQQ   274.55 (-0.35%)
AAPL   150.74 (+0.21%)
MSFT   238.20 (+0.12%)
META   136.94 (-2.47%)
GOOGL   98.02 (-0.73%)
AMZN   114.89 (+0.98%)
TSLA   275.97 (+0.23%)
NVDA   122.90 (-1.81%)
NIO   17.63 (-0.06%)
BABA   79.22 (+0.53%)
AMD   66.66 (-1.91%)
T   15.73 (-1.75%)
MU   49.06 (-2.08%)
CGC   2.76 (-2.82%)
F   11.99 (-2.60%)
GE   64.77 (+0.34%)
DIS   98.35 (-1.16%)
AMC   7.37 (-7.76%)
PYPL   85.07 (-2.18%)
PFE   43.84 (-0.54%)
NFLX   224.57 (-0.81%)
NASDAQ:JNCE

Jounce Therapeutics - JNCE Stock Forecast, Price & News

$2.69
-0.04 (-1.47%)
(As of 09/26/2022 12:30 PM ET)
Add
Compare
Today's Range
$2.69
$2.78
50-Day Range
$2.73
$4.92
52-Week Range
$2.69
$9.81
Volume
207 shs
Average Volume
327,521 shs
Market Capitalization
$139.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Jounce Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
298.6% Upside
$11.00 Price Target
Short Interest
Healthy
6.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.29) to ($2.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

414th out of 1,069 stocks

Biological Products, Except Diagnostic Industry

66th out of 171 stocks

JNCE stock logo

About Jounce Therapeutics (NASDAQ:JNCE) Stock

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

Jounce Therapeutics Inc Stock Quote JNCE
4 Analysts Have This to Say About Jounce Therapeutics
Jounce Therapeutics Q1 2022 Earnings Preview
See More Headlines
Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Company Calendar

Last Earnings
8/04/2022
Today
9/26/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JNCE
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+308.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-90,870,000.00
Pretax Margin
-400.86%

Debt

Sales & Book Value

Annual Sales
$26.91 million
Book Value
$4.37 per share

Miscellaneous

Free Float
48,117,000
Market Cap
$139.06 million
Optionable
Optionable
Beta
1.10

Key Executives

  • Dr. Richard Murray Ph.D. (Age 63)
    Pres, CEO & Director
    Comp: $887.4k
  • Mr. Hugh M. Cole (Age 57)
    Chief Operating Officer
    Comp: $607.44k
  • Dr. Elizabeth G. Trehu M.D. (Age 62)
    Chief Medical Officer
    Comp: $639.6k
  • Dr. James Patrick Allison Ph.D.
    Founder
  • Dr. Thomas F. Gajewski M.D.
    Ph.D., Founder
  • Dr. Robert D. Schreiber Ph.D.
    Founder
  • Dr. Drew Mark Pardoll M.D.
    Ph.D., Founder
  • Dr. Padmanee Sharma M.D.
    Ph.D., Founder
  • Dr. Louis M. Weiner M.D. (Age 70)
    Founder
  • Ms. Kimberlee Cobleigh Drapkin CPA (Age 54)
    CPA, CFO & Treasurer













JNCE Stock - Frequently Asked Questions

Should I buy or sell Jounce Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JNCE shares.
View JNCE analyst ratings
or view top-rated stocks.

What is Jounce Therapeutics' stock price forecast for 2022?

7 Wall Street analysts have issued 12-month target prices for Jounce Therapeutics' stock. Their JNCE share price forecasts range from $5.00 to $17.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 308.9% from the stock's current price.
View analysts price targets for JNCE
or view top-rated stocks among Wall Street analysts.

How have JNCE shares performed in 2022?

Jounce Therapeutics' stock was trading at $8.35 at the beginning of 2022. Since then, JNCE shares have decreased by 67.8% and is now trading at $2.69.
View the best growth stocks for 2022 here
.

When is Jounce Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our JNCE earnings forecast
.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) announced its earnings results on Thursday, August, 4th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.03.

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jounce Therapeutics own?
When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cowen AND Company LLC (5.50%), Citadel Advisors LLC (3.28%), Assenagon Asset Management S.A. (2.65%), FMR LLC (2.45%), State Street Corp (1.27%) and Congress Asset Management Co. MA (1.05%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third.
View institutional ownership trends
.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $2.69.

How much money does Jounce Therapeutics make?

Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $139.06 million and generates $26.91 million in revenue each year. The company earns $-90,870,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Jounce Therapeutics have?

The company employs 137 workers across the globe.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com.

This page (NASDAQ:JNCE) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.